Rate of infections in patients with myelofibrosis treated with Ruxolitinib and conventional therapy: a retrospective,monocentric study

Trial Profile

Rate of infections in patients with myelofibrosis treated with Ruxolitinib and conventional therapy: a retrospective,monocentric study

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Myelofibrosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jul 2017 New trial record
    • 25 Jun 2017 Results (n=22) of a cohort assessing rate of infections, presented at the 22nd Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top